Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

~ 44.0% objective response rate and 10.3-month median progression-free survival observed in non-small cell lung cancer (NSCLC) cohort ~ Phase 3 registration-enabling trial planned in first-line metastatic NSCLC

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here